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Depression is the most commonly encountered psy-chiatric disorder in clinical practice. The Epidemio-
logic Catchment Area study — an extensive community 
survey — estimated a one-month prevalence of 1.6% 
and a lifetime rate of 4.4%. According to a World 
Health Organization forecast, the incidence of this con-
dition is increasing so fast that by the year 2020 it will 
likely rank as the second most serious illness in terms 
of the global burden of disease. About 15% of patients 
with primary affective disorders commit suicide and, 
for those who survive, their life span is shorter and 
morbidity rates are high. Depression as a comorbidity 
intensifies the suffering of physically ill patients. These 
individuals generally have poor outcomes — postmyo-
cardial patients who are depressed have a much higher 
mortality rate compared to their nondepressed coun-
terparts. Further, depressed medically ill patients are 
high utilizers of the healthcare system and present a 
special challenge during their rehabilitative treatment. 
Many patients respond poorly to antidepressants, 
even when they're combined with proven forms of effec-
tive psychotherapy. For others who are acutely suicidal 
or suffer from rapid and unrelenting decline, electro-
convulsive therapy (ECT) is their only life-saving option. 
Studies show success 
Numerous trials have proven ECT to be effective in 
various types of depression with particular success in 
treating delusional forms and those with catatonic fea-
tures. As maintenance therapy, it can also prevent relapse 
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and recurrence. Although its use in other psychiatric 
conditions isn't widespread, it's known to be beneficial 
in severe forms of mania and schizophrenia that are 
unresponsive to conventional pharmacotherapy. Studies 
provide evidence that the modern form of ECT is safe 
and effective in depressed patients with medical ill-
nesses, and the same results have been observed in the 
elderly. In effect, ECT has broad applications and ben-
efits that have been proven through numerous ran-
domized controlled trials and many years of clinical 
experience. Unfortunately, dramatization of ECT by the 
popular press and movie industry portrays it as a risky 
and, at times, punitive mode of treatment. This myth is 
further perpetuated by radical patient rights groups 
who protest regularly at psychiatric conferences. 
Significant progress has been made since the intro-
duction of ECT in 1938 by Cereletti and Binni. Patients 
are carefully selected and prepared. Modern ECT ma-
chines efficiently deliver accurate doses of electrical 
current while patients are closely monitored in a safe 
environment. Contemporary methods of anesthesia at-
tenuate the motor aspects of the seizure. These measures 
have dramatically reduced the rates of complications and 
mortality. Developments and observations of the effects 
of ECT on brain activity have set the stage for a novel and 
less interventionist method of treatment referred to as 
transcranial magnetic stimulation. This innovative ap-
proach, a natural outgrowth of ECT, will revolutionize 
the management of depressive disorders in the future. 
Despite public skepticism and opposition from various 
quarters, ECT has prevailed for over half a century as 
an acceptable form of treatment for certain psychiatric 
disorders. This is testimony to its safety and efficacy, 
as well as to the accomplishments of its proponents. 
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con There's a lack of 
evidence for benefit 
BY BRAD HAGEN, RN, PhD 
ECT advocates assert that it's safe and effective, de-spite considerable evidence that casts doubts on 
these claims. While ECT has come a long way since its 
first use, there are still many reasons for skepticism. 
ECT is so commonplace that many forget what it ac-
tually is — the use of electricity to induce a grand mal 
epileptic seizure. The unorthodoxy of this treatment 
should give us pause. Most of us avoid direct contact 
with electricity and, with the exception of cardioversion 
—which requires less voltage and has clear justification 
for its application — shocking patients is generally con-
sidered illogical. Further, in neurology the accepted ap-
proach is to reduce, not induce multiple seizures. 
Although numerous theories have emerged, there's 
still no sound physiologic explanation for why ECT 
might help in depression. Clear justifications are also 
lacking for why it's used in so many dissimilar condi-
tions, such as depression, mania and schizophrenia. 
While studies find that 50 to 85% of patients claim 
ECT is helpful, this 'efficacy' is likely due to a power-
ful placebo effect. While antidepressants also demon-
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strate a high success rate, meta-analysis of drug stud-
ies show only an 18% improvement over placebo, and 
even less if active placebos (with side effects) are used. 
If a simple pill produces such a strong impact, consider 
the potential placebo effect of ECT with its electrodes, 
machines and intravenous devices. Some studies try to 
control for this by using sham ECT — administration 
of anesthetic, but no electric shock — but patients usu-
ally know which treatment they've received due to the 
presence of post-ECT headaches and amnesia. 
Drawbacks are unsolved 
Proponents cite studies that demonstrate ECT's ability to 
resolve symptoms of depression by 75-95%, but are less 
vocal about the remarkably high relapse rate. Further, 60 
years of research has failed to show any benefit after four 
weeks post-treatment. ECT is also promoted as lifesav-
ing for acutely suicidal patients. The majority of studies, 
however, report that it doesn't prevent suicide in de-
pressed patients and in some cases may actually increase 
the risk — Ernest Hemingway claimed that ECT-related 
memory loss drove him to take his life. 
Is ECT safe? If the same 100 to 450 volts (0.75-0.9 amps) 
were applied to the chest, the results would likely be 
fatal. When administered to the head, however, the 
mortality rate is very low. The two most common side 
effects associated with ECT — headaches and memory 
impairment — are usually transient. There are no reliable 
studies, however, on the long-term effects of repeated 
(maintenance) ECT, particularly among the elderly 
who are at greater risk for cardiac mortality and mor-
bidity. Although contentious, it's also speculated that 
continuous use of ECT may cause brain damage. 
Finally, if ECT were truly safe and effective, why 
isn't it used extensively? Less than 8% of all U.S. psy-
chiatrists perform ECT, and a disproportionate num-
ber of them are men. ECT also isn't applied uniformly 
across all patient populations — elderly women tend 
to be a common target group. With the current lack of 
knowledge about its mode of action and clear evidence 
for its long-term benefit, we should be more skeptical 
and cautious about ECT use for the time being. pe 
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